• 1
    Andrade C. A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427.
  • 2
    Sekijuma Y, Yoshida K, Tokuda T, Ikeda S. Familial transthyretin amyloidosis. In: PagonRA, BirdTC, DolanCR, StephensK, eds. Gene Reviews. Seattle, WA: University of Washington; 2005.
  • 3
    Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-1116.
  • 4
    Adams D, Slama M, Samuel D. Liver transplantation for familial amyloid polyneuropathy [in French]. Presse Med 2010; 39: 17-25.
  • 5
    Furtado A, Tomé L, Oliveira FJ, Furtado E, Viana J, Perdigoto R. Sequential liver transplantation. Transplant Proc 1997; 29: 467-468.
  • 6
    Wilczek HE, Larsson M, Yamamoto S, Ericzon BG. Domino liver transplantation. J Hepatobiliary Pancreat Surg 2008; 15: 139-148.
  • 7
    Familial Amyloidotic Polyneuropathy World Transplant Registry and Domino Liver Transplant Registry. Accessed August 2010.
  • 8
    Azoulay D, Samuel D, Castaing D, Adam R, Adams D, Said G, Bismuth H. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg 1999; 189: 584-593.
  • 9
    Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352: 2356.
  • 10
    Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006; 6: 2512-2515.
  • 11
    Barreiros AP, Geber C, Birklein F, Galle PR, Otto G. Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. Liver Transpl 2010; 16: 109.
  • 12
    Ericzon BG. Domino transplantation using livers from patients with familial amyloidotic polyneuropathy: should we halt? Liver Transpl 2007; 13: 185-187.
  • 13
    Samuel D, Adams D. Domino liver transplantation from familial amyloidotic polyneuropathy donors: how close is the Damocles sword to the recipient? Transpl Int 2007; 20: 921-923.
  • 14
    Furtado AJ. Domino liver transplantation using FAP grafts. HUC experience—hopes and realities. Amyloid 2003; 10( suppl 1): 84-87.
  • 15
    Bittencourt PL, Couto CA, Leitão RM, Siqueira SA, Farias AQ, Massarollo PC, Mies S. No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 (mean 24) month follow-up. Amyloid 2002; 9: 194-196.
  • 16
    Sousa MM, Ferrão J, Fernandes R, Guimarães A, Geraldes JB, Perdigoto R, et al. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest 2004; 84: 865-873.
  • 17
    Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007; 13: 215-218.
  • 18
    Yamamoto S, Wilczek HE, Iwata T, Larsson M, Gjertsen H, Söderdahl G, et al. Long-term consequences of domino liver transplantation using familial amyloidotic polyneuropathy grafts. Transpl Int 2007; 20: 926-933.
  • 19
    Adams D, Lacroix C, Antonini T, Lozeron P, Denier C, Epelbaum S, et al. Risk of developing de novo amyloid deposits and induced polyneuropathy in FAP domino liver recipients [abstract]. Eur J Neurol 2009; 16( suppl 13): 16-54.
  • 20
    Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D, Saraiva MJ. Familial amyloid polyneuropathy: receptor for advanced glycation end-products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001; 21: 7576-7586.
  • 21
    Said G. Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 2003; 10( suppl 1): 7-12.
  • 22
    Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl 2009; 15: 1229-1335.
  • 23
    Koike H, Ando Y, Ueda M, Kawagashira Y, Iijima M, Fujitake J, et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 2009; 287: 178-184.
  • 24
    Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994; 31: 351-354.
  • 25
    Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15: 181-186.
  • 26
    Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002; 58: 1001-1007.
  • 27
    Amante MF, Trigo P, Lendoire J, Imventarza O, Parisi C. Transthyretin familial amyloidotic polyneuropathy: histopathological study of the explanted livers. Ann Hepatol 2003; 2: 171-174.
  • 28
    Miller SR, Sekijima Y, Kelly W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004; 84: 545-552.
  • 29
    Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidosis. Curr Pharm Des 2008; 14: 3219-3330.
  • 30
    Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236-249.